Drug Development & Delivery’s annual report highlights the formulation, development and manufacturing offerings from some of the leading CDMOs in the industry to address some of the most common challenges – from complex highly potent compounds to poor solubility.
Read the article to find out how we mitigate time, cost and risk and helped a client convert a drug-in-capsule to a formulated capsule for a Phase 2a clinical study.
